Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AnTolRx logo — Innovative therapies for autoimmune diseases through targete...

AnTolRx

Innovative therapies for autoimmune diseases through targeted immune-regulation using proprietary nanoparticle-based solutions.

Founded 2015 Series A Total: $4.00M Biotechnology, Health Care

General Information

Company Name AnTolRx
Founded Year 2015
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care
Funding Stage Series A
Social

Get notified when AnTolRx moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About AnTolRx

AnTolRx is a biotechnology and healthcare startup founded in 2015, pioneering innovative therapies for autoimmune diseases. The company's slogan, "Innovative therapies for autoimmune diseases through targeted immune-regulation using proprietary nanoparticle-based solutions," encapsulates its mission. AnTolRx's approach involves developing nanoparticle-based treatments to achieve antigen-specific immune tolerance, addressing the limitations of traditional therapies that can cause severe side effects by broadly suppressing the immune system. The company's proprietary drug development technique specifically targets harmful immune cells, delivering a unique tolerogenic signal to induce an anti-inflammatory response. AnTolRx secured a significant $4.00M Series A investment on 08 September 2016 from notable investors including Orion Healthcare Equity Partners, JDRF (The Juvenile Diabetes Research Foundation), and Pfizer Venture Investments. This funding serves as a testament to the confidence these industry players have in AnTolRx's pioneering approach and potential to revolutionize autoimmune disease treatment.

Taxonomy: Nanoparticle-based therapies, Autoimmune diseases, Immune regulation, Tolerogenic signal, Drug development, Antigen-specific immune tolerance, Precision medicine, Innovative therapies, Immunotherapy, Healthcare innovation

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 3
Investor
•••• •••• 		08 Sep 2016

AnTolRx Alternatives & Competitors

AnTolRx vs
Repertoire Immune Medicines
Repertoire Immune Medicines United States

Repertoire is a biotechnology company creating a new category of immune medicines for cancer and aut...

Series B
86 employees
Biotechnology, Health and Wellness
AnTolRx vs
3T Biosciences
3T Biosciences United States

3T is an immunotherapy company developing next-generation, transformative therapies for broad patien...

Series A
26 employees
Biopharma, Biotechnology
AnTolRx vs
Immune Tolerance Network
Immune Tolerance Network

The Immune Tolerance Network (ITN) is a collaborative network for clinical research, funded by the N...

36 employees

FAQ About AnTolRx

Innovative therapies for autoimmune diseases through targeted immune-regulation using proprietary nanoparticle-based solutions.
AnTolRx was founded in 2015.
AnTolRx operates in the following industries: Biotechnology, Health Care.
AnTolRx has completed 1 funding round, raising a total of $4.00M. The latest funding stage is Series A.
Top alternatives and competitors to AnTolRx include Repertoire Immune Medicines, 3T Biosciences, Immune Tolerance Network, GraphTx, Revolo Biotherapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AnTolRx and Repertoire Immune Medicines are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors AnTolRx and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy